Status:
UNKNOWN
Pioglitazone Decreases Visceral Fat Metabolism
Lead Sponsor:
Kurume University
Conditions:
To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
Eligibility:
All Genders
35-58 years
Phase:
NA
Brief Summary
Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume, but it its effect on me...
Eligibility Criteria
Inclusion
- Subjects between the ages of 35 and 85 years
- Subjects with impaired glucose tolerance and type 2 diabetes
Exclusion
- Subjects with insulin treatment
- Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery disease, symptomatic cerebrovascular disease
- Subjects taking more than three antidiabetic medications
- Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones within 8 weeks prior to randomization
- Subjects with cardiac failure (New York Heart Association Class \> III) or left ventricular dysfunction (LVEF \< 40%)
- Subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01819402
Start Date
March 1 2012
Last Update
March 27 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kurume University
Kurume, Japan, 830-0011